Effect of a low dose whey/guar preload on glycemic control in people with type 2 diabetes-a randomised controlled trial

Nutrition Journal

Research

Claire Galbraith¹  Leah Coles¹  Peter M Clifton² 

[1] Baker IDI Heart and Diabetes Institute, Prahan, VIC, Australia;University of South Australia, North Terrace, GPO Box 2471, 5001, Adelaide, SA, Australia;

关键词: Whey;    Guar;    Glycemic control;    Type 2 diabetes;   

DOI  :  10.1186/1475-2891-13-103

 received in 2014-08-04, accepted in 2014-10-15,  发布年份 2014

来源: Springer

【 摘 要 】

ObjectiveLarge preloads of protein and fat have been shown to lower glucose after a carbohydrate-rich meal in people with type 2 diabetes but add a considerable energy burden. Low calorie preloads [<5% of daily energy intake] have been tested in this study in people with prediabetes and with type 2 diabetes.Research design and methodsThis was an unblinded randomised crossover study with two placebo days and two active treatment days. Glucose was measured for 3 hours with fingerprick samples as well as continuous glucose monitoring [CGMS]. Twenty-four subjects with pre-diabetes or moderately controlled type 2 diabetes [fasting glucose < 10 and HbA1c < 8.5%] were recruited. The preload contained 17 g whey protein plus 3 g lactose and 5 g guar, and 1 g flavour material [including sucralose] dissolved in 150 ml cold water or 150 ml cold water with no additives. The breakfast test meal consisted of 2 slices of bread, margarine and jam [3 slices for men] with the test drink 15 minutes beforehand.ResultsPeak fingerprick glucose was reduced by 2.1 mmol/L at 45 min [p < 0.0001]. Average fingerprick glucose over 3 hours was reduced by 0.8 mmol/L [p = 0.0003]. There was no difference between those with diabetes or prediabetes or those on medication or not on medication.ConclusionsAn 80 kcal whey protein/fibre preload can lower average glucose over 3 hours by 0.8 mmol/L. If used long term before at least two carbohydrate-rich meals/day this preload could lower HbA1c by up to 1%.Trial registrationThe trial was registered with the Australian New Zealand Clinical Trials Registry number ACTRN12612001251819.

【 授权许可】

CC BY   
© Clifton et al.; licensee BioMed Central Ltd. 2014